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t10c12-CLA maintains higher bone mineral density during aging
by modulating osteoclastogenesis and bone marrow adiposity
Md M Rahman, Ganesh V Halade, Paul J Williams, and Gabriel Fernandes
Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd
Curl Drive, Texas 78229-3900, USA

Abstract
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Conjugated linoleic acid (CLA) has been shown to positively influence calcium and bone
metabolism. Earlier, we showed that CLA (equal mixture of c9t11-CLA and t10c12-CLA) could
protect age-associated bone loss by modulating inflammatory markers and osteoclastogenesis.
Since, c9t11-CLA and t10c12-CLA isomers differentially regulate functional parameters and gene
expression in different cell types, we examined the efficacy of individual CLA isomers against
age-associated bone loss using 12 months old C57BL/6 female mice fed for 6 months with 10%
corn oil (CO), 9.5% CO + 0.5% c9t11-CLA, 9.5% CO + 0.5% t10c12-CLA or 9.5% CO + 0.25%
c9t11-CLA + 0.25% t10c12-CLA. Mice fed a t10c12-CLA diet maintained a significantly higher
bone mineral density (BMD) in femoral, tibial and lumbar regions than those fed CO and c9t11CLA diets as measured by dual-energy-x-ray absorptiometry (DXA). The increased BMD was
accompanied by a decreased production of osteoclastogenic factors i.e. RANKL, TRAP5b, TNFalpha and IL-6 in serum. Moreover, a significant reduction of high fat diet-induced bone marrow
adiposity was observed in t10c12-CLA fed mice as compared to that of CO and c9t11-CLA fed
mice, as measured by Oil-Red-O staining of bone marrow sections. In addition, a significant
reduction of osteoclast differentiation and bone resorbing pit formation was observed in t10c12CLA treated RAW 264.7 cell culture stimulated with RANKL as compared to that of c9t11-CLA
and linoleic acid treated cultures. In conclusion, these findings suggest that t10c12-CLA is the
most potent CLA isomer and it exerts its anti-osteoporotic effect by modulating osteoclastogenesis
and bone marrow adiposity.
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Introduction
Osteoporosis constitutes a major worldwide public health burden, characterized by enhanced
skeletal fragility. Nearly 200 million people worldwide, including approximately 25 million
Americans, suffer from osteoporosis, a thinning of the bones. This leads to osteoporotic
fracture, which is largely a problem of the elderly, particularly women [May et al., 1994].
Osteoporosis related costs are a major economic concern, expected to increase to $131
billion by year 2050 [Johnell, 1997]. After attaining peak bone mass between the ages of
20–30, both men and women start losing bone at a rate of about 0.5% to 1% yearly
[McGarry and Kiel, 2000]. Bone mineral density (BMD) appears to decline with increasing
age [Chevalley et al., 1991]. The decline in BMD and increased fracture risk are an
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inevitable part of the aging process, requiring new strategies for its prevention. However,
osteoporosis is easier to prevent than to treat. Dietary therapy and/or lifestyle changes are
considered as viable alternatives to minimize bone loss and to decrease the necessity for
drug therapy to prevent osteoporosis. It is well established that dietary patterns modulate
BMD in the elderly [Tucker et al., 2002]. Our recent study with CLA showed that it
increases bone mass in both cancellous and cortical bones in young male Balb/C and aging
female C57BL/6 mice [Banu et al., 2006a; Rahman et al., 2007].
Bone metabolism is the combination of bone resorption by osteoclasts and bone formation
by osteoblasts. Increase in bone resorption is considered as the main contributor of bone
loss, leading to osteoporosis; this loss is accompanied by increased bone marrow adiposity.
The type of dietary fat intake and lifestyle choices are important determinants of age-related
osteoporosis. The fats present in Western diets consist predominantly of saturated fatty acids
and also n-6 polyunsaturated fatty acids (PUFA’s), derived from sources like corn,
safflower, sunflower and soybean oils [Simopoulos, 1991]. The predominant n-6 fatty acid
in these oils is linoleic acid (18:2n-6, LA), which is found to act as a pro-inflammatory fatty
acid [Rahman et al., 2007].
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CLA refers to a mixture of positionally and geometrically conjugated dienoic isomers of
linoleic acid (LA). The c9t11-CLA isomer represents approximately 80% of the total
isomers in dairy and ruminant fats; whereas, c9t11- and t10c12-CLA are equally abundant
(usually 30–40% of each isomer) in commercial mixtures [Andreoli et al., 2009]. In recent
decades, interest in CLA has increased due to its many bioactive properties related to health.
In fact, very recently CLA has received FDA approval as GRAS (Generally Recognized As
Safe) category for use in various food supplements. The benefits seem to be very clear,
especially in some experimental animal models [Andreoli et al., 2009; Banu et al., 2006b;
Bhattacharya et al., 2006b; Bhattacharya et al., 2005; Rahman et al., 2007]. In some animal
models, dietary CLA reduce carcinogenesis, decrease body fat, increase lean body mass,
enhance feed efficiency, protect against oxidative stress, modulate circulating lipids and
prevent impaired glucose tolerance in diabetes [Bhattacharya et al., 2006a]. Several of these
effects are controversial. In addition, some adverse results in some animal models:
hepatomegaly [Tsuboyama-Kasaoka et al., 2000] and hepatic steatosis [Belury and KempaSteczko, 1997] have been noted. However, because of its approval by FDA as a GRAS
category, it can be used in different food products.
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Currently, the focus has been on the effects of CLA on skeletal health. Recently, it has been
reported that dietary CLA may positively benefit BMD in postmenopausal women
[Brownbill et al., 2005]. Increased whole body-ash in young mice fed diet with CLA
supplementation suggests that CLA may enhance bone mineralization and protect against
bone loss [Park et al., 1997]. Anhydrous butterfat, a rich natural source of CLA, also
stimulated the rate of bone formation in young growing chicks by modulating prostaglandin
(PG) E2, which plays an important role in the local regulation of bone formation and bone
resorption [Watkins et al., 1997]. However, while CLA has been shown to increase bone
mass, ash and/or mineral content in some studies with young growing experimental animals
(mice [Park et al., 1997] and pigs [Thiel-Cooper et al., 2001]), others have reported a lack of
effect in rats [Kelly, 2001; Li et al., 1999] and in pigs [Demaree et al., 2002]. We have
demonstrated the beneficial effect of CLA against aging associated BMD loss in C57BL/6
mice [Rahman et al., 2007]. However, the effect of individual CLA isomers on age
associated bone loss has not been investigated thoroughly. Hence, the present study was
designed to examine the effect of corn oil (n-6 fatty acid), as a control for a westernized diet,
and CLA isomers (c9t11-CLA and t10c12-CLA) on BMD in 12 month old female C57BL/6
mice fed for 6 months. The primary objective of the present investigation is to unravel the
isomer specific effect of CLA on age associated bone loss in female C57BL/6 mice.
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Materials and Methods
Animals
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Eleven month-old female C57BL/6 mice were purchased from Jackson Laboratories (Bar
Harbor, Maine 04609 USA). The age and weight matched animals were housed in a
standard controlled animal care facility in cages (5 mice/cage) and fed a standard diet
(Harlan Teklad LM-485) for one month. The animals were maintained in temperature
controlled room (22–25°C, 45% humidity) on a 12:12-h dark-light cycle. National Institutes
of Health guidelines were strictly followed, and all the studies were approved by the
Institutional Laboratory Animal Care and Use Committee of the University of Texas Health
Science Center at San Antonio (San Antonio, TX). At completion of twelve month of age,
the mice were divided into four groups, containing 15 mice in each. The mice were fed the
American Institute of Nutrition (AIN)-93 diet, supplemented with CLA isomers and corn oil
(CO) ad libitum for 6 months. Body weights were recorded weekly.
Diet preparation
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The AIN-93 diets were supplemented with 10% CO as a fat diet. Four types of diets were
(1) AIN-93 diet supplemented with 10% CO (CO) (2) AIN-93 diet supplemented with 9.5%
CO and 0.5% c9t11-CLA (c9t11) (3) AIN-93 diet supplemented with 9.5% CO and 0.5%
t10c12-CLA (t10c12) and (4) AIN-93 diet supplemented with 9.5% CO, 0.25% c9t11-CLA
and 0.25% t10c12-CLA (CLA mix). The CLA isomers were supplied by Lipid Nutrition,
Channahon, IL, USA. The c9t11-CLA enriched diet contained approximately 61% of c9t11CLA isomer and t10c12-CLA contained 71 % of t10c12-CLA. The composition of the semipurified diet per 100 g of diet was described earlier [Halade et al., 2009a; Halade et al.,
2009b]. Fresh diet was provided everyday in the afternoon (between 3–4pm) and leftover
food was removed daily to prevent rancidity.
Measurement of bone mineral density (BMD)
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA) Lunar
PIXImus (GE, Madison, WI) and data was analyzed with PIXImus software, as described
previously [Bhattacharya et al., 2006b; Bhattacharya et al., 2005; Rahman et al., 2007].
Scanning was performed first at baseline (12 month of age) and again at the end of 6 months
of experimental diet’s feeding, as a final value.
Serum cytokines measurement
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Serum cytokine levels for TNF-α and IL-6 were measured by standard ELISA techniques,
using commercially available BD OptEIA ELISA kits for TNF-α and IL-6 (BD Biosciences,
San Diego, CA), as described previously [Bhattacharya et al., 2006c].
Serum RANKL and TRAP5b measurement
Serum receptor activator of NF-κB ligand (RANKL) and tartrate resistant acid phosphatase
(TRAP) were measured using mouse free sRANKL and mouse TRAP5b ELISA assay kits
from Immunodiagnostic System (IDS) Inc. (Fountain Hills, AZ), according to the
manufacturer’s instructions.
Tissue collection for biochemical analysis and bone histology
After completion of experimental diet feeding, mice were sacrificed. Blood was obtained by
intraorbital capillary plexus and serum was collected and stored at −80°C. Bones were
collected, and fixed in 10% neutral buffered formalin (NBF). Sections of bone were
processed and embedded in paraffin and stained for Oil Red O.
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Oil Red O staining of bone sections
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Rear leg bone specimens (10 mice/group) from each dietary group were collected and
trimmed of excess tissue and fixed in 10% NBF for 48 hrs at room temperature (RT). Bones
were then placed in solution 1 (500ml 70% ethylene glycol, 5 grams linoleic acid, mixed for
1 hr at RT, allowed to stand several hours at RT in a separatory funnel, and the bottom layer
drawn off) for 3 days at 56°C. Bones were then rinsed for at least 8 hrs in several changes of
70% ETOH at RT; then rinsed with several changes of water for at least 8 hrs, then
decalcified with 2% chromic acid for 40 hrs at 4°C, and rinsed with water for 8 hrs, followed
by incubation with 5% sodium bicarbonate/water for 24 hrs at RT. The bones were then
rinsed with several changes of water for 24–72 hrs at RT. Bones were then placed in 70%
ETOH, processed and embedded in paraffin, following standard protocol. Paraffin blocks
were microtomed at 5μm sections on glass slides and allowed to dry overnight. Sections
were then deparaffinized through xylene and graded alcohols. Sections were incubated in
Oil red solution (Oil red O 0.7g and 200ml isopropanol, mixed, left overnight at RT, then
filtered, and diluted in 120ml water, left overnight at 4°C, and filtered) for 1 hr at RT.
Sections were then rinsed with water until clear, and counterstained with hematoxylin and
crystal mounted.
Osteoclast like cell formation assay
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RAW 264.7 cells were suspended in phenol free α-MEM containing 10% fetal bovine serum
(FBS) and plated at a concentration of 2 × 104 cells/well in a 48-well culture dish. Cells
were cultured in the presence of 50 ng/ml RANKL and incubated for 24 hrs. Various
concentrations of LA, c9t11-CLA, t10c12-CLA or CLA-mix were added to the cultures. The
medium and factors were replaced every 3 days. After 5 days of culture in the presence of
RANKL and isomers, the cells were fixed and stained for TRAP, using TRAP staining kit
from Sigma (St Louis, MO), according to the manufacturer’s instruction [Rahman, 2006].
TRAP+ cells with more than 3 nuclei were counted as TRAP +ve multinucleated cells
(MNCs).
Pit formation assay
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RAW 264.7 cells were suspended in phenol free α-MEM containing 10% FBS and plated at
a concentration of 1 × 104 cells/well in an Osteoclast Activity Assay Substrate 24-well plate
(OAAS™) (OCT USA Inc, CA 90501), in the presence or absence of 50 ng/ml RANKL and
incubated for 24 hrs. Subsequently, 50 μM of LA, c9t11-CLA, t10c12-CLA or CLA-mix
were added to the cultures. Half of the medium with fresh factors were replaced every 2
days. After 7 days of culture, the plates were washed in 6% sodium hypochlorite solution to
remove the cells. The resorbed areas on the plates were captured with a digital camera
attached to a microscope and analyzed by Metaview Image Analysis System [Rahman,
2006]. Results were expressed in % resorption area.
Statistical analysis
Data are presented as mean values ± S.E.M. Differences among the groups (CO, c9,t11CLA, t10,c12-CLA and CLA mix) were tested by one-way analysis of variance and
student’s t-test. Newman-Keuls post hoc test were used followed by ANOVA if multiple
correlations were made. A p value < 0.05 was considered statistically significant. The
analyses were performed with Graphpad prism for Windows (La Jolla, CA).
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Results
Effect of dietary fat on BMD
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BMD was measured at 12 month of age (baseline) and after 6 months of experimental diets
(final value). Data were shown in Table 1. A notable reduction of BMD in lumbar regions of
bone with age was observed in CO fed mice. However, a significant protection of BMD loss
in lumbar regions of bone was observed with t10c12-CLA. With c9t11-CLA and CLA-mix
no statistically significant protection was observed in these regions as some slight although
insignificant protection is indicated. Slight but insignificant increase in BMD value in distal
femoral metaphysis and tibial diaphysis regions was observed in t10c12-CLA and CLA-mix
supplemented mice as compared to CO and c9t11-CLA supplemented mice. However, there
was significant increase in femoral diaphysis region in t10c12-CLA supplemented mice as
compared to CO and c9t11-CLA supplemented mice. Some slight although insignificant
increase in BMD value in this region was noted in CLA-mix supplemented mice. A similar
kind of protection of BMD loss in different regions of bones was also observed in a separate
experiment with 18 month old C57BL/6 female mice fed for 3 months with CO and CLA
isomers diets (data not shown). These data suggest that t10c12-CLA and CLA-mix fed aging
mice maintain higher cancellous and cortical BMD compared to CO and c9t11-CLA fed
mice. Therefore, t10c12-CLA isomer might be the active component of CLA-mix in
maintaining higher BMD during aging.
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Effect of CLA on serum cytokines
To examine if CLA isomers differentially affect proinflammatory cytokines, we determined
the serum IL-6 and TNF-α levels in c9t11-CLA, t10c12-CLA, CLA-mix and CO fed mice.
Serum TNF-α and IL-6 levels were decreased significantly in both c9t11-CLA and t10c12CLA fed mice, including CLA-mix fed mice, compared to CO fed mice (Figure 1A & B).
The results indicate that both CLA isomers equally down-regulate the osteoclastogenic
proinflammatory cytokines, IL-6 and TNF-α. CLA-mix fed mice exhibited little bit more
reduction of these cytokines in serum than individual isomers do. Since both the CLA
isomers independently reduce the pro-inflammatory cytokines production in C57BL/6 mice,
CLA-mix fed mice exhibit more reduction of these cytokines may be because of the
combined effects of these isomers.
Effect of CLA on serum sRANKL and TRAP5b
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To examine if CLA isomers differentially affect the pivotal osteoclastogenic factor,
RANKL, we examined the level of sRANKL by ELISA. Interestingly, RANKL level was
significantly less in t10c12-CLA and CLA-mix fed mice than in CO and c9t11-CLA fed
mice (Figure 2A). As serum TRAP5b levels indicate the current status of bone resorbing
osteoclast’s function, i.e. TRAP activity, we measured the serum TRAP5b level as a bone
resorption marker, by means of a mouse TRAP5b ELISA kit. Similarly, we found a
significant reduction of TRAP5b activity in t10c12-CLA and CLA-mix fed mice (Figure
2B). These results support the notion that t10c12-CLA isomer might be the active
component of CLA-mix, modulating osteoclastogenesis.
Effect of CLA isomers on bone marrow adiposity
Bone marrow adipogenesis is a normal physiologic process in all mammals. Adipocyte in
bone marrow regions increases with age. As both osteoblasts and adipocytes differentiate
from a common progenitor cell, the more adipocytes mean less osteoblasts. Age associated
increase in adipocytes is considered as one of the vital factors for less bone formation during
aging. CLA is a well known dietary fatty acid capable of reducing adipogenesis. Therefore,
we examined if CLA has any effect in reducing age associated adipocytes generation in

J Cell Physiol. Author manuscript; available in PMC 2012 September 1.

Rahman et al.

Page 6

NIH-PA Author Manuscript

bone marrow regions. We also examined if CLA isomers differentially affect this parameter.
Interestingly, we found that only t10c12-CLA and CLA-mix are capable of reducing bone
marrow adipocytes, compared to CO fed control (Figure 3). However, c9t11-CLA alone did
not show any notable reduction of bone marrow adipocytes (Figure 3). These results indicate
that t10c12-CLA is the active component of CLA-mix, exerting its effect by inhibiting
adipogenesis; thereby, helping osteogenesis.
Effect of CLA isomers on RANKL-stimulated TRAP-positive osteoclast like cells formation
in RAW 264.7 cells
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As RAW 264.7 cells differentiate into osteoclasts in the presence of RANKL, we examined
the effect of CLA isomers on the osteoclast differentiation of RAW 264.7 cells, in the
presence of RANKL, using TRAP staining. Previously, we showed that CLA-mix dose
dependently inhibited total TRAP activity and multinucleated osteoclast like cells formation
in RANKL stimulated RAW 264.7 cells. But it was not known whether c9t11-CLA and
t10c12-CLA differentially affect osteoclast differentiation in RAW264.7 cells. In this study,
we examined the effect of individual isomers on RANKL stimulated osteoclast
differentiation of RAW264.7 cells. As seen in the in vivo experiments, only t10c12-CLA
and CLA mix are capable of inhibiting osteoclast differentiation in RAW264.7 cells, as
compared to the linoleic acid control (Figure 4). There was no inhibitory effect observed in
c9t11-CLA treated cultures. These results indicate, for the first time, that t10c12-CLA is the
active component of CLA-mix, exerting its effect by modulating bone resorbing osteoclast
formation.
Effect of CLA isomers on bone resorption in RANKL-stimulated RAW 264.7 cells
As we have already seen that t10c12-CLA dramatically inhibits the formation of osteoclast
like multinucleated cells, which are believed to be responsible for bone resorption, we
further examined if CLA isomers differentially affect these mature osteoclasts to resorb
bone. We used calcium phosphate coated culture plates to stimulate RAW264.7 cells, with
RANKL, to differentiate into mature osteoclasts, having bone resorbing capacity. RANKL
stimulated RAW 264.7 cells showed a number of resorption areas (Figure 5A). Cultures
treated with t10c12-CLA and CLA-mix showed significantly reduced numbers and areas of
resorption pits, compared to cultures treated with either RANKL alone or together with LA
(Figure 5B). There was no notable reduction of bone resorbing pit formation in c9t11-CLA
treated cultures. These results indicate that t10c12-CLA is the active component of CLAmix, exerting its effect by inhibiting osteoclastic bone resorption.

Discussion
NIH-PA Author Manuscript

The progressive loss of bone mass is believed to play a major role in the pathogenesis of
frailty and functional impairment that occurs with advancing age. Our hypothesis is that a
high fat diet, already prevalent in the American population when supplemented with CLA,
counteracts inflammation and related excessive osteoclastic bone resorption, and as a result,
improves bone mass and strength. Accordingly, we first investigated the isomer specific
effect of CLA on the prevention of age associated bone loss in aging C57BL/6 mice since
previous studies showed that CLA protects bone mineral density loss [Bhattacharya et al.,
2006a; Bhattacharya et al., 2005; Rahman et al., 2007]. These earlier studies however, were
conducted with an equal mixture of c9t11-CLA and t10c12-CLA isomers. Mixed CLA
isomers variably affect bone resorption in animals and decrease osteoclast formation and
activity in murine osteoclasts. Such variable effects may be due to the different isomers
present in commercial preparations of CLA, and the specific effects of the predominant
individual isomers, c9t11-CLA and t10c12-CLA are not clear. Here we show for the first
time effect of individual CLA isomers in attenuating age-related bone loss. In earlier study,
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we showed that C57BL/6 mice when fed with 10% CO exhibit increased levels of
inflammation, obesity and osteoporosis [Halade et al.; Halade et al.]. In this study, we
observed that inclusion of CLA isomers, especially t10c12-CLA in the high-fat-diet (10%
CO), maintained a higher BMD during aging, most likely by modulating inflammatory
mediators, bone marrow adiposity and osteoclastogenesis. In a previous study, both c9t11CLA and t10c12-CLA isomers are reported to inhibit osteoclast formation and activity in
human CD14+ monocytes [Platt and El-Sohemy, 2009a]. In our study, we found that only
the t10c12-CLA isomer exhibits anti-osteoclastogenic effects in RANKL stimulated murine
macrophage cell line RAW264.7. These variations could be due to the different cell types
used. However, in both studies CLA-mix showed inhibition of osteoclastogenesis.
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In this study we have chosen 12 month old female C57BL/6 mice. After attaining peak bone
mass between the ages of 20–30, both men and women start losing bone at a rate of about
0.5% to 1% yearly [McGarry and Kiel, 2000]. Based on a comparative biology calculation,
12 months of mouse age is equivalent to 35 years of human age, which is full adulthood.
Similarly 18 months of mouse age corresponds to 52 year of human age. Women at the age
of menopause at around 50–55 year old start losing BMD at an accelerated rate. To protect
this accelerated BMD loss at the age of menopause preventive medicine/supplement should
be taken from the adult age to at least premenopausal age. Therefore, in this study, we chose
to use 12 month female C57BL/6 mice to feed for 6 months with experimental diets
supplemented with CLA isomers in order to compare these data directly to human studies.
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In this study, we focused primarily on the protective effect of CLA isomers against bone
resorption; however, CLA has been reported to enhance immunity and bone formation
[Brownbill et al., 2005]. Current evidence suggests that CLA may help decrease bone loss,
by reducing prostaglandins in bone tissue [Watkins and Seifert, 2000; Watkins et al., 1997]
or by enhancing calcium absorption [Kelly et al., 2003]. CLA was also reported to increase
the expression of the bone formation markers, osteocalcin and alkaline phosphatase, in
murine osteoblastic cell lines [Watkins et al., 2001]. Very recently, Park et al reported that in
male mice, t10c12-CLA but not c9t11-CLA is capable of enhancing bone formation in the
presence of 1% calcium supplementation which is consistent with our findings that the
t10c12-CLA may be the useful CLA isomer capable of improving BMD [Park and Terk].
We analyzed the effects of individual isomers c9t11-CLA and t10c12-CLA on BMD using
DEXA in the cancellous and cortical bones of the femur, tibia and lumbar spine in aging
C57BL/6 female mice. When 12-month-old mice were fed either CO or CO+c9t11-CLA or
CO+t10c12-CLA or CO+CLA-mix for 6 months, t10c12-CLA and CLA-mix fed mice were
found to maintain a higher BMD in pure cortical and cancellous bones. These findings
correlated with decreased levels of pro-inflammatory cytokines TNF-α and IL-6 in the
serum of t10c12-CLA and CLA-mix fed mice, as compared to CO control mice. However,
serum TNF-α and IL-6 levels were significantly lower in c9t11-CLA fed mice, without
affecting osteoclastogenesis. Slightly enhanced but non-significant reduction of both TNF-α
and IL-6 levels was noted in CLA-mix group as compared to individual isomers groups.
This effect could be due to combined effect of c9t11-CLA and t10c12-CLA. Antiinflammatory effect of both c9t11-CLA and t10c12-CLA isomers have been reported [Platt
and El-Sohemy, 2009a]. There are evidences that antiosteoclastogenic drugs protect bone
loss by blunting the production of IL-1, IL-6, and TNF-α [Manolagas and Jilka, 1995; Poli et
al., 1994], which stimulate stromal cell production of RANKL and macrophage colony
stimulating factor (M-CSF), the sole regulators of osteoclastogenesis [Cappellen et al., 2002;
Hofbauer et al., 1999; Kimble et al., 1996]. Cheng et al reported that CLA inhibits LPSinduced inflammatory events in the macrophage cell line RAW 264.7, an osteoclast
precursor cell, by negatively regulating inflammatory mediators and NF-κB activation
[Cheng et al., 2004] [Iotsova et al., 1997]. Differentiation of osteoclasts is regulated by the
osteoclastogenic factor RANKL [Suda et al., 1992; Suda, 1999]. We therefore examined the
J Cell Physiol. Author manuscript; available in PMC 2012 September 1.
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level of RANKL in the serum of CLA isomers fed mice. Significantly lower levels of serum
RANKL was observed in t10c12-CLA and CLA-mix fed animals compared to CO and
c9t11-CLA fed animals. This result indicates that t10c12-CLA is likely the active
component in CLA, mediating protection against age-associated BMD loss by modulating
osteoclastogenesis. However, further study should be undertaken to determine the effect of
individual isomers on bone formation parameters.
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Here we also determined the anti-bone resorbing capacity of individual isomers by
measuring the level of serum TRAP5b. TRAP is primarily a cytochemical marker of
macrophages, osteoclasts and dendritic cells [Lamp and Drexler, 2000]. Although
osteoclasts contain abundant TRAP and are responsible for bone resorption, the total TRAP
activity in the serum as measured by colorimetric methods, little reflects bone turnover
[Igarashi et al., 2002]. TRAP 5 can be further separated into 5a and 5b by electrophoresis.
TRAP 5b is considered a prominent product of osteoclasts. Thus serum TRAP 5b levels
might reflect the status of bone resorption more closely [Igarashi et al., 2002]. Therefore, the
reduction of TRAP5b activity in the t10c12-CLA and CLA-mix fed mice suggests a
reduction of bone resorbing activity. These findings indicate the possible mechanisms of age
associated bone loss protection by t10c12-CLA and CLA-mix may be the modulation of
osteoclastogenic bone resorption by altering osteoclastogenic factors. To determine the
effect of individual isomers on osteoclastogenesis, we stimulated RAW 264.7 cells with
RANKL in the presence of individual isomers, and found a dramatic inhibition of TRAP +ve
osteoclast cells formation in t10c12-CLA and CLA-mix treated cultures, as compared to
linoleic acid and c9t11-CLA treated cultures. However, Platt et al found that both c9t11CLA and t10c12-CLA inhibit osteoclast formation from CD14+ monocytes, with c9t11CLA showing a greater effect. We did not find an inhibitory effect with c9t11-CLA in the
RAW264.7 cells. These variations could be due to different cell types used although both
are of monocytic lineage. Furthermore, using RAW264.7 cells, we analyzed the bone
resorbing pit formation in CLA isomers treated cultures and found a dramatic reduction of
bone resorbing pit formation in t10c12-CLA and CLA-mix treated cells, as compared to CO
and c9t11-CLA treated cells. However, Platt and colleagues found a similar level of
inhibition of osteoclast activity with both c9t11-CLA and t10c12-CLA in CD14+
monocytes. Our results indicate that t10c12-CLA isomer is the active isomer in the CLAmix, in inhibiting RANKL stimulated osteoclast differentiation and function in RAW264.7
cells.
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Bone marrow adipogenesis is a normal physiologic process in all mammals, although its full
function is unknown. With aging, the composition of bone marrow shifts to favor the
presence of adipocytes, osteoclast activity increases, and osteoblast function declines,
resulting in osteoporosis [Rosen et al., 2009; Rosen and Klibanski, 2009]. The mesenchymal
stem cell is the marrow precursor for adipocytes, as well as osteoblasts. There is an inverse
relationship between adipocytes and osteoblasts within the bone marrow cavity. Increased
bone marrow adiposity is believed to be the reason for less bone formation during aging.
Decreased bone mass is observed in age-related osteoporosis, due to increased marrow
adipose tissue [Pei and Tontonoz, 2004]. Due to CLA’s capability to reduce adipogenesis, it
is possible that it may reduce adipocytes in bone marrow regions. Interestingly, we found
that both t10c12-CLA and CLA mix fed mice exhibited fewer adipocytes in bone marrow
regions, whereas c9t11-CLA did not appear to have any effect. It is well established that
only t10c12-CLA is capable of reducing the abdominal adipocytes [Halade et al., 2009a;
Halade et al., 2009b; Wang and Jones, 2004]. However, here we show for the first time that
t10c12-CLA, but not c9t11-CLA, is able to reduce bone marrow adiposity during aging.
This may be one of the mechanisms by which t10c12-CLA exerts its effect against ageassociated BMD loss. Thus, t10c12-CLA will negatively modulate adipogenesis, while
promoting osteogenesis. Unraveling the interface between bone and fat at a molecular and
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cellular level is likely to lead to a better understanding of several diseases and to the
development of drugs, for both osteoporosis and obesity [Rosen et al., 2009; Rosen and
Klibanski, 2009]. However, more studies are needed to understand the interrelationship
among hematopoietic, osteoblastic, and adipogenic cells within the marrow niche [Rosen et
al., 2009; Rosen and Klibanski, 2009].
In our study shows that t10c12-CLA and CLA mix can prevent age-associated BMD loss by
inhibiting the production of pro-inflammatory and pro-osteoclastogenic factors, osteoclastic
bone resorption and bone marrow adiposity. It is very likely that these agents may inhibit
bone resorption by suppressing NF-κB and MAPK signaling pathways. Since these agents
also reduce bone marrow adiposity, it is also likely that they may up-regulate Wnt signaling
to promote osteoblastogenesis as osteoblasts and adipocytes arise from the same progenitor
cells, mesenchymal stem cells. Recently, Platt et al showed that t10c12-CLA isomer is
capable of escalating osteoblast differentiation in human mesenchymal stem cells by upregulating Wnt signaling [Platt and El-Sohemy, 2009b]. However, isomer specific effects
have to be analyzed in future studies.
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In conclusion, our study shows that the t10c12-CLA isomer is the active component of the
CLA-mix that exerts an anti-osteoporotic effect. However, the t10c12-CLA isomer alone is
known to have some adverse effects, such as: fatty liver formation, insulin resistance, etc.,
which can be corrected by combining with the c9t11-CLA isomer, which is known to
improve insulin sensitivity, as well as fatty liver formation [Moloney et al., 2007]. As CLAmix also showed an equal efficacy as of t10c12-CLA isomer alone; therefore, the CLA-mix
could be an ideal dietary supplement to protect/delay age-associated BMD loss. Moreover,
the majority of currently available anti-osteoporotic drugs exert its effect by inhibiting
osteoclastogenesis, meaning less bone resorption, without stimulating bone formation. Old
dense bone may not represent strong bone. Therefore, agents that modulate both bone
resorption and bone formation might provide a better option for maintaining the quality and
strength of bone during aging. We and others have shown that CLA inhibits
osteoclastogenesis [Platt and El-Sohemy, 2009a; Rahman et al., 2007; Rahman et al., 2006]
and others have shown its positive effects on bone formation [Platt and El-Sohemy, 2009b;
Watkins and Seifert, 2000; Watkins et al., 1997]. We recently showed that c9t11-CLA and
t10c12-CLA also act differentially in vivo. c9t11-CLA had no effect in reducing fat mass
and improving BMD, whereas t10c12-CLA was able to reduce fat mass and improve lean
mass in young and middle aged mice [Halade et al., 2009a; Halade et al., 2009b].
Furthermore, our very recent findings that CLA-mix can modulate bone marrow adiposity
also support the notion that CLA may help bone formation. Thus, CLA-mix could be a
promising dietary supplement to prevent age associated BMD loss by modulating both bone
resorption and bone formation. More studies with different ratios of c9t11-CLA and t10c12CLA are warranted to establish their mechanisms of action in modulating bone mass, muscle
mass and fat mass during aging.
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Figure 1. Effect of CLA isomers on the production of inflammatory cytokines
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Twelve month old C57BL/6 mice were fed with experimental diets for 12 months and serum
was collected after sacrifice. Serum was analyzed for TNF-α (A) and IL-6 (B) using
standard ELISA kits. Each bar represents the mean ± S.E.M. of 5 samples. Value with
different superscripts are significantly different at p<0.05 by Newman-Keuls’ one way
ANOVA with multiple comparison test. A. CO vs. c9t11-CLA (p<0.05), CO vs. t10c12CLA (p<0.05), CO vs. CLA-mix (p<0.01). B. CO vs. c9t11-CLA (p<0.001), CO vs. t10c12CLA (p<0.001), CO vs. CLA-mix (p<0.001).
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Figure 2. Effect of CLA isomers on osteoclastogenic factor and bone resorption marker
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Twelve month old C57BL/6 mice were fed with experimental diets for 12 months and serum
was collected after sacrifice. Serum was analyzed for RANKL (A), as an osteoclastogenic
factor, and for TRAP5b (B), as a bone resorbing factor. Each bar represents the mean ±
S.E.M. of 8 samples. Value with different superscripts are significantly different at p<0.05
by Newman-Keuls’ one way ANOVA with multiple comparison test. A. CO vs. t10c12CLA (p<0.01), CO vs. CLA-mix (p<0.05), c9t11-CLA vs. CLA-mix (p<0.05), c9t11-CLA
vs. t10c12-CLA (p<0.05). B. CO vs. t10c12-CLA (p<0.05), CO vs. CLA-mix (p<0.05),
c9t11-CLA vs. CLA-mix (p<0.05), c9t11-CLA vs. t10c12-CLA (p<0.01).
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Figure 3. Effect of CLA isomers on bone marrow adipocytes
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Twelve month old C57BL/6 mice were fed with experimental diets for 12 months. Bones
(femur and tibia) were collected after sacrifice and fixed in 10% neutral buffered saline
(NBF). Sections of bone were processed and embedded in paraffin and stained for Oil Red
O. Arrow shows the adipocytes in the bone marrow cavity (A). The data represent the mean
± S.E.M. of adipocyte area of the upper half of the diaphysis of femur from 3 mice per group
(B). Value with different superscripts are significantly different at p<0.05 by NewmanKeuls’ one way ANOVA with multiple comparison test. 10X magnification. CO vs. t10c12CLA (p<0.05), CO vs. CLA-mix (p<0.05), c9t11-CLA vs. t10c12-CLA (p<0.05).
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Figure 4. Effect of CLA isomers on TRAP-positive osteoclast formation

RAW 264.7 cells were suspended in phenol free α-MEM containing 10% FBS and plated at
a concentration of 2 × 104 cells/well into a 48-well culture dish (Corning, NY), with
different concentrations of linoleic acid (LA), c9t11-CLA, or t10c12-CLA at a concentration
of 50 μM, in the presence of 50 ng/ml RANKL. The medium and factors were replaced
every 3 days. After 5 days of culture with factors, the cells were fixed and stained for TRAP
using TRAP staining kit, according to the manufacturer’s instruction. TRAP+ cells, with
more than 3 nuclei, were counted as TRAP +ve multinucleated cells (MNCs). Each bar
represents the mean ± S.E.M. of 3 independent triplicate cultures. Value with different
superscripts are significantly different at p<0.05 by Newman-Keuls’ one way ANOVA with
multiple comparison test. RL, Receptor activator of NF-κB. LA vs. t10c12-CLA (p<0.001),
LA vs. CLA-mix (p<0.001), c9t11-CLA vs. t10c12-CLA (p<0.001), c9t11-CLA vs. CLAmix (p<0.001).

NIH-PA Author Manuscript
J Cell Physiol. Author manuscript; available in PMC 2012 September 1.

Rahman et al.

Page 17

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 5. Effect of CLA isomers on bone resorbing pit formation
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RAW 264.7 cells were suspended in phenol free α-MEM containing 10% FBS and plated at
a concentration of 1 × 104 cells/well on an Osteoclast Activity Assay Substrate (OAAS™)
plate (OCT USA Inc, CA 90501) in the presence of LA (50μM), c9t11-CLA (50μM), or
t10c12-CLA (50μM), with 50 ng/ml RANKL. These plates were coated with artificial bone
(calcium phosphate coating). Half of the medium with factors was replaced every 2 days.
After 7 days of culture in the presence of factors, the plates were washed in 6% sodium
hypochlorite solution to remove the cells. The resorbed areas on the plates were captured
with a digital camera attached to the microscope and analyzed by Metaview Image Analysis
System (A). Each bar represents the mean ± S.E.M. of 3 independent triplicate cultures (B).
Value with different superscripts are significantly different at p<0.05 by Newman-Keuls’
one way ANOVA with multiple comparison test. RL, Receptor activator of NF-κB. 10X
magnification. LA vs. t10c12-CLA (p<0.001), LA vs. CLA-mix (p<0.001), c9t11-CLA vs.
t10c12-CLA (p<0.001), c9t11-CLA vs. CLA-mix (p<0.001).
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0.045±0.001
3.26±1.56

Final

% Difference

0.044±0.002

Baseline

0.096±0.001

Baseline

15.05±2.85

7.12±3.44

% Difference

% Difference

0.098±0.002

Final

0.065±0.001

0.092±0.001

Baseline

Final

−1.193±6.00

% Difference

0.056±0.001

0.058±0.002

Final

Baseline

10.50±5.25

0.059±0.002

Baseline

7.07±3.54

0.059±0.003

−1.13±7.52

% Difference

% Difference

4.30±4.34

0.057±0.003

Final

0.102±0.003

0.064±0.003

0.058±0.001

Baseline

Final

2.50±4.80

−2.20±5.33

% Difference

3.64±1.50

0.046±0.002

0.045±0.001

15.86±3.97

0.065±0.001

0.056±0.001

6.97±1.44

0.104±0.002

0.093±0.001

8.51±1.82

0.098±0.001

0.091±0.001

0.056±0.002

0.061±0.001

0.060±0.002

0.059±0.003

Final

0.059±0.001

c9t11-CLA

0.061±0.001

Baseline

CO

Diet

9.12±1.68

0.047±0.001

0.044±0.001

22.70±2.80c

0.070±0.002b

0.057±0.001

11.04±1.40

0.106±0.001

0.099±0.001

11.82±2.30

0.104±0.001c

0.092±0.001

26.60±5.16a

0.074±0.001a

0.059±0.001

20.15±5.83c

0.072±0.002a

0.061±0.001

20.77±4.00 a

0.076±0.002a

0.064±0.001

t10c12-CLA

9.05±1.49

0.048±0.002

0.045±0.002

16.65±3.24

0.067±0.001

0.058±0.001

15.02±2.23

0.110±0.003

0.096±0.003

10.14±2.07

0.106±0.004

0.096±0.002

15.23±13.98

0.063±0.003

0.058±0.003

20.44±10.47

0.076±0.003c

0.064±0.001

9.08±4.25

0.070±0.003

0.067±0.003

CLA-mix

p<0.01 and

p<0.001,

b

a

12 month old mice were fed for 6 months with experimental diets. Values are means ± SEM, n = 15. Each group was compared to CO control group by Student’s t-test. p<0.05 was considered significant.

TD (g/cm2)

FD (g/cm2)

(g/cm2)

L4 (g/cm2)

L3 (g/cm2)

L2 (g/cm2)

Parameter

Effect of CLA isomers on bone mineral density (BMD) (g/cm2) in C57BL/6 mice.
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DFM: Distal femoral metaphysis; PTM: Proximal tibial metaphysis; FD: Femoral diaphysis; TD: Tibial diaphysis; L2: Lumbar vertebra 2; L3: Lumbar vertebra 3; L4: Lumbar vertebra 4.

NIH-PA Author Manuscript

c
p<0.05.
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